Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Core Viewpoint - Xilio Therapeutics, Inc. has successfully closed a public offering of pre-funded warrants and common stock warrants, raising approximately $50 million, with potential total gross proceeds of up to $150 million by the end of 2026 if all warrants are exercised for cash [1][5]. Group 1: Offering Details - The offering included pre-funded warrants to purchase 66,676,000 shares of common stock, along with Series A, B, and C warrants, all sold together at a combined public offering price of $0.7499 [2][4]. - The Series B warrants are exercisable at $0.75 per share between November 1, 2025, and December 2, 2025, potentially generating an additional $50 million if fully exercised [4]. - The Series C warrants are also exercisable at $0.75 per share between June 1, 2026, and December 2, 2026, with the same potential additional proceeds of $50 million if fully exercised [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Xilio's product candidates and for working capital and general corporate purposes [5]. Group 3: Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [8].